4月东方生物宣布收到纽交所通知函件，指出其因未按时提交年报（Form 10-K）不满足纽交所交易规则，同时根据纽交所有关规定，公司将获得6个月的额外时间来满足交易规则，即必须在2012年10月29日前提交年度报告。

此前3月东方生物因安永华明会计师事务所在审计财报时出现不一致情况，推迟原定于3月15日递交的2011财年年报（Form 10-K），同时管理层及董事会审计委员宣布审计委员会将开始调查存在的问题，具体调查期限并不确定。东方生物自此遭纽交所停牌处理，停牌前报1.52美元。

（来源：i美股）

北京时间3月16日，东方生物因安永华明会计师事务所在审计财报时出现不一致情况，推迟原定于3月15日递交的2011财年年报（Form 10-K），同时管理层及董事会审计委员宣布审计委员会将开始调查存在的问题，具体调查期限并不确定。东方生物自此遭纽交所停牌处理，停牌前报1.52美元。

（i美股）

（i美股）

Yan Gao此前为该公司会计团队的高级会计师，负责监督财报等工作。该任命2月22日生效。

此外，该公司原首席营销官YangYang因个人原因辞职，董事会在2月22日批准。

（i美股 李雪/编译）

目前该公司一共拥有大约78,503,381股普通股，合股完成后将拥有39,251,867股普通股。

该股票美东时间周二跌4.21%报0.68美元，当日成交量为54.66万，超过平均成交量36.83万。此前该股票因股价长期低于1美元收到退市警告。

（i美股 李雪/编译）

公司季度总营收5390万美元，较上年同期的9150万美元大幅下降41%；

毛利润为2520万美元，上年同期为4730万美元；毛利率46.7%也低于上年同期的51.7%；

归属于股东的净利润770万美元，折合每股收益0.1美元；上年同期净利润为420万美元，折合每股收益0.06美元。

东方生物Q3财报英文版

（i美股 Jocelyn编译）

受此影响，该公司周四盘后涨9.4%报0.64美元，该股周三涨2.63%报0.58美元。

9月28日该公司发布声明，称公司由于在截止至2011年9月19日的30个连续交易日股价低于1美元、不满足上市标准而收到纽交所通知。

（i美股 李雪）

按照纽交所规定，三乐源须在接到该通知之日起10日内予以回复（截止日期2011年10月5日），否则将自动进入从纽交所的暂停交易及退市程序。三乐源称将利用所有可行手段恢复股价，并将如期回复通知。

（i美股）

财报显示，东方生物第二季度实现：

— 营收5410万美元，远低于去年同期的7730万美元；

— 毛利润2580万美元，低于去年同期的3980万美元；

— 毛利率47.8%，去年同期是51.5%；

— 运营利润630万美元，去年同期是910万美元；

— 扣除少数股东权益的净利润为360万美元，摊薄后每股收益为0.05美元，去年同期是510万美元，0.07美元。

（i美股）

东方生物2011财年第二季度财报（英文版）

NEW YORK, May 10, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE:AOB - News), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that the Company's Zhibai Dihuang Pill ("ZD Pill") and Ciwujia Tablet ("CWJ Tablet") have been approved for sale as traditional Chinese medicine ("TCM") in Hong Kong by Chinese Medicine Council of Hong Kong, ("CMCHK").

Guangxi Lingfeng Pharmaceutical, ("GLP"), a wholly owned subsidiary of AOBO, is the manufacturer of ZD Pill, which is formulated entirely with pure natural ingredients and herbs. The medicine is indicated for the treatment of hot flush, night sweat, dry mouth, sore throat, etc.

Harbin Three Happiness Bioengineering ("3H"), a wholly owned subsidiary of AOBO, is the manufacturer of CWJ Tablet, which is formulated entirely with pure natural ingredients and herbs. The medicine is indicated for the treatment of fatigue, poor appetite, back pain and knee pain, and insomnia.

Mr. Tony Liu, Chairman and CEO of AOBO, commented, "We are honored to receive the approval for sales of additional two TCMs in Hong Kong. These newly-approved ZD Pill and CWJ Tablet, together with our LWDH mini Ball approved in March, are among the very few TCM products which are manufactured in mainland Chinaand approved for marketing and sales in Hong Kong."

2011年一季度财报业绩：

营收为5200万美元，较去年同期的5370万美元，下滑3.2%；

毛利润为2510万美元，较去年同期的2820万美元，下滑10.7%；

毛利率为48.2%，去年同期为52.5%；

运营利润为550万美元，较去年同期的640万美元下滑14.1%；

归属于控股权益（controlling interest ）的净利润为90万美元，去年同期为310万美元，同比下滑71%；摊薄每股收益为0.01美元，去年同期为0.04美元。

东方生物2011年一季度财报（英文版）

（i美股 陈群超编译）

First Quarter 2011 Financial Performance

In the first quarter of 2011, revenue decreased to $52.0 million from $53.7 million in the same period of 2010.

• The Company generated revenue of $48.7 million from its manufacturing business in the first quarter of 2011 compared with $50.5 million in the prior year period.  Revenue from pharmaceutical products decreased 4.7% to $39.0 million from $40.9 million in the prior year period. Nutraceutical products generated revenue of approximately $9.8 million in the first quarter of 2011, an increase of 1.2% from $9.7 million in the prior year period.  The revenue performance reflects the combined results of the Company's continuous marketing efforts, new product launches, and expanding coverage in rural areas.  This was offset by the impact from the Company's strategic shift of revenue mix toward higher-margin products to minimize the impact from the increased costs of certain raw materials.
• The Company generated $3.3 million from its distribution business, Nuo Hua, in the first quarter of 2011, compared to $3.2 million in the prior year period.

Gross profit in the first quarter of 2011 was $25.1 million compared to $28.2 million in the first quarter of 2010. Gross margin was 48.2% compared to 52.5% in the prior year period.  The margin pressure was mainly caused by a higher proportion of generic product sales in the rural market, the increased costs of certain raw materials, as well as the new levied urban construction and maintenance tax and educational surcharge.

Operating income in the first quarter of 2011 decreased to $5.5 million compared with $6.4 million in the prior year period.  Total operating expenses decreased 10.7% to $19.5 million from $21.9 million in the prior year period.  Selling, general and administrative expenses were $11.2 million, or 21.6% of total revenue, compared to $10.7 million, or 20.0% of total revenue, in the prior year period.  Advertising expense decreased to $3.8 million in the first quarter of 2011 compared to $6.7 million in the prior year period, reflecting reduced advertising efforts on OTC drugs to correspond to the Company's selective product sales strategy. Research and development expenses were $2.7 million compared to $2.8 million in the prior year period.  Management continued to implement stringent cost control measures which offset the increased labor costs.

Net income attributable to controlling interest for the first quarter of 2011 was $0.9 million, or $0.01 per diluted share, compared to $3.1 million, or $0.04 per diluted share, in the prior year period.  

Balance Sheet

As of March 31, 2011, the Company had $111.4 million in cash and cash equivalents, and generated approximately $21.6 million of operating cash flow during the first quarter of 2011. Working capital was $162.9 million as of March 31, 2011, compared to $162.2 million as of December 31, 2010.

Mr. Tony Liu, Chairman and Chief Executive Officer of AOB, commented, "We are pleased with our financial performance despite the increasingly challenging economic and regulatory environment in China and worldwide.  Our first quarter results reflect our continuing efforts on profitability focus and cost control.  We dynamically adjusted our product mix to minimize the negative impact from the increased costs of certain raw materials and the government's price reduction on certain drugs.  In addition, we believe our continued investments in CAPEX and R&D will give us a competitive advantage in for the long term, especially under the stricter regulatory environment."

Conference Call

The Company will hold a conference call at 8:00 am ET on Tuesday, May 10, 2011, to discuss its results.  Listeners may access the call by dialing 1-877-299-4454 or 1-617-597-5447 for international callers, access code: 91826695.  A webcast will also be available through AOB's website at www.bioaobo.com.  A replay of the call will be available through May 17, 2011.  Listeners may access the replay by dialing 1-888-286-8010 or 1-617-801-6888 for international callers, access code: 86841058.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.  

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.  Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements.  The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward looking statements in this press release.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

美国：1-877-299-4454；国际：1-617-597-5447；密码：91826695

或登录 【www.bioaobo.com】注册后收听网上直播。

收听电话会议的投资者请至少提前10分钟拨入电话或登陆页面下载必要音频软件。

电话会议结束后直至美东部时间5月17日23:59，可拨打：1-888-286-8010或1-617-801-6888，收听电话会议重播。